Testing higher-dose ivermectin for COVID-19

This trial studies new drug treatment plans for people who currently have COVID-19. If it works better than standard care, it could improve recovery for patients.

This trial tests adding ivermectin (a common anti-parasitic drug) to your current immunotherapy. The hope is that ivermectin may help the immunotherapy work better against your cancer.

This early-phase trial tests a new drug (called B10-FC) to see if it's safe and how the body processes it. It is given once to healthy adults, and later to people with mild or moderate COVID-19 who are at higher risk of getting very sick.

This early-stage study tests COVID-19 treatments in people who have recently developed symptoms and who test positive for the virus. It aims to find safer, more effective options for preventing worsening disease, especially in higher-risk groups.

This trial tests an investigational medicine called ibuzatrelvir for adults with COVID-19 who have a weakened immune system. The study aims to see if it helps them recover and avoid severe illness.

This trial tests whether Codivir can help people hospitalized with moderate COVID-19 recover better than a placebo (inactive pill). It will compare outcomes while participants receive standard hospital care.